William Blair Lifts Earnings Estimates for Upstream Bio

Upstream Bio, Inc. (NASDAQ:UPB) – Research analysts at William Blair raised their Q1 2025 EPS estimates for shares of Upstream Bio in a research note issued to investors on Wednesday, March 12th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($0.35) for the quarter, up from their prior estimate of ($0.40). The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio’s Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($1.91) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($1.53) EPS and FY2029 earnings at ($1.75) EPS.

Upstream Bio Price Performance

Shares of UPB stock opened at $9.61 on Friday. The business has a 50 day moving average of $9.76. Upstream Bio has a 52 week low of $6.65 and a 52 week high of $29.46.

Institutional Trading of Upstream Bio

A number of large investors have recently made changes to their positions in the stock. VR Adviser LLC bought a new stake in shares of Upstream Bio in the fourth quarter worth approximately $37,735,000. Woodline Partners LP bought a new stake in shares of Upstream Bio in the fourth quarter worth approximately $8,656,000. Sandia Investment Management LP bought a new stake in shares of Upstream Bio in the fourth quarter worth approximately $164,000. Nuveen Asset Management LLC bought a new stake in shares of Upstream Bio in the fourth quarter worth approximately $371,000. Finally, Orbimed Advisors LLC bought a new stake in shares of Upstream Bio in the fourth quarter worth approximately $93,603,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.